Market withdrawal of Baycol (cerivastatin)-Bayer Inc.
Therapeutic Products Directorate (TPD) and Biologics and Genetic
Therapies Directorate (BGTD) posts safety alerts, public health advisories,
press releases and other notices from industry as a service to health professionals,
consumers, and other interested parties. Although TPD and BGTD approve therapeutic
products, TPD and BGTD do not endorse either the product or the company. Any questions
regarding product information should be discussed with your health professional.
This is duplicated text of a letter from BAYER INC.
Contact the company for a copy of any references, attachments or enclosures. |
August 8, 2001
Dear Healthcare Professional:
I am writing to inform you of very important new safety information about Baycol (cerivastatin) and rhabdomyolysis.
Rhabdomyolysis is a serious, potentially fatal, adverse effect of all statin drugs, including Baycol. It can occur
with statin monotherapy, though the risk appears to be increased significantly by concomitant use of gemfibrozil.
Our ongoing scrutiny of post-marketing reports of rhabdomyolysis, including fatalities, has revealed an increased
reporting rate of rhabdomyolysis with Baycol relative to other statins, especially when gemfibrozil is co-prescribed.
These data also suggest an increased reporting rate of rhambdomyolysis at the 0.8 mg dose of Baycol alone.
Bayer Inc. has already placed a contraindication in the
Baycol Product Monograph against coprescription with gemfibrozil and communicated
to healthcare professionals warning against coprescription of these two
drugs. Despite these and other actions, Bayer has continued to receive
reports of rhabdomyolysis when gemfibrozil is prescribed as a co-medication.
Since the co-prescription of Baycol and gemfibrozil has continued despite
communications by Bayer against this practice, the company has decided
to take the following voluntary action to prevent further cases of rhabdomyolysis:
Effective immediately, Bayer has discontinued the marketing
and distribution of all dosage strengths of Baycol. Patients who are currently
taking Baycol should have their Baycol discontinued and be switched to
an alternative therapy.
Bayer is taking this action as part of an ongoing commitment to patients
and their healthcare providers to ensure patient safety.
It is important that you forward any adverse event information
associated with the use of Baycol to Bayer Inc. at 1-800-265-7382. You
can also report the information directly to Health Canada by fax at 613-957-0335.
If you have further questions regarding this action on
Baycol, please contact Bayer Inc. at 1-800-265-7382.
Yours sincerely
original signed by
Neil S. Maresky, M.B., B.Ch.
Vice President
Medical and Scientific Affairs
Any suspected adverse drug reactions can be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Bureau of Licensed Product Assessment
Therapeutic Products Directorate
HEALTH CANADA
Address Locator: 0201C2
OTTAWA, Ontario, K1A 1B9
Tel: (613) 957-0337 or Fax: (613) 957-0335
Toll free for consumers and health professionals:
Tel: 866 234-2345, Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
The ADR Reporting Form can be found in The Canadian Compendium of Pharmaceuticals
and Specialties, or on the TPD web site, along with the ADR Guidelines.
|
|
